Asthma Trial, Recruiting (NCT06840717)

Asthma Trial, Recruiting NCT06840717 Sponsor: Guangzhou Institute of Respiratory Disease Condition: Asthma

Printed from Voxsanity (voxsanity.com.au) — NCT06840717 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Asthma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Children who have been diagnosed with asthma based on the 2023 GINA guidelines (an internationally recognised set of standards for diagnosing asthma)
Children whose wheezing and coughing has been confirmed as asthma, with other causes such as throat infections, airway abnormalities present from birth, or an object stuck in the airway having been ruled out
Children who have not taken antibiotics or steroid medications (taken by mouth or injection) in the two weeks before entering the trial
Children who do not have other significant health conditions, such as a heart condition present from birth, pneumonia, acid reflux disease, or muscle development problems

Who may not be able to join:

Children who have been taking immunosuppressants, antibiotics, or similar medications over a long period of time before joining the trial
Children who have a primary immune deficiency condition (a condition where the immune system does not work properly from birth)
Children or their families who are unable to cooperate with the study requirements or who do not wish to participate

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 13719240285

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06840717

Sponsor: Guangzhou Institute of Respiratory Disease

Phase: Not Applicable

Status: Recruiting

Condition: Asthma

Trial contact: 13719240285

More information: https://clinicaltrials.gov/study/NCT06840717

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Children who have been diagnosed with asthma based on the 2023 GINA guidelines (an internationally recognised set of standards for diagnosing asthma)
Children whose wheezing and coughing has been confirmed as asthma, with other causes such as throat infections, airway abnormalities present from birth, or an object stuck in the airway having been ruled out
Children who have not taken antibiotics or steroid medications (taken by mouth or injection) in the two weeks before entering the trial
Children who do not have other significant health conditions, such as a heart condition present from birth, pneumonia, acid reflux disease, or muscle development problems

Who may not be able to join:

Children who have been taking immunosuppressants, antibiotics, or similar medications over a long period of time before joining the trial
Children who have a primary immune deficiency condition (a condition where the immune system does not work properly from birth)
Children or their families who are unable to cooperate with the study requirements or who do not wish to participate

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Guangzhou Institute of Respiratory Disease

Registry

ClinicalTrials.gov

Start date

30 January 2024

Est. completion

30 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

type 2 inflammation indicators; pulmonary function indicators; single nucleotide polymorphism

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov